Literature DB >> 20696814

The association of the angiopoietin/Tie-2 system with the development of metastasis and leukocyte migration in neuroendocrine tumors.

Nicté Figueroa-Vega1, Angel Díaz, Magdalena Adrados, Cristina Alvarez-Escolá, Amalia Paniagua, Julián Aragonés, Elena Martín-Pérez, Susanna Leskela, Ricardo Moreno-Otero, Roberto González-Amaro, Mónica Marazuela.   

Abstract

The aim of this study was to explore the possible involvement of the angiopoietin (Ang)-1, -2/Tie-2 system in the development, growth, and metastases evolution of gastroenteropancreatic-neuroendocrine tumors (GEP-NETs). We prospectively examined the serum levels of Tie-2, Ang-1, and Ang-2 by ELISA in 42 patients with proven GEP-NETs and 27 controls. We also determined the expression of the Ang/Tie-2 system in freshly isolated peripheral blood monocytes and in tumor cells from malignant primary tumors and/or liver metastases samples from GEP-NET patients by flow cytometry and/or RT-PCR. Furthermore, the function of the Ang/Tie-2 system in monocytes from controls and patients was assessed by a chemotaxis assay. GEP-NET patients showed enhanced serum levels of soluble form of Tie-2 (sTie-2), Ang-1, and Ang-2 (P<0.05 in all cases), compared to controls. sTie-2 and Ang-2 levels were significantly higher in GEP-NETs with metastases compared to those with no metastases. In addition, a significant correlation was detected between Ang-2 levels and chromogranin A or sTie-2 concentrations or 5-hydroxy-indole acetic acid excretion (r=0.71, r=0.60, and r=0.81 respectively, P<0.01 in all cases). Furthermore, we observed an enhanced expression of Ang-1, Ang-2, and Tie-2 in freshly isolated tumor cells from GEP-NET both by immunohistochemistry and by RT-PCR. Interestingly, an enhanced expression and function of Tie-2 was detected in monocytes from GEP-NET patients. Our data suggest that the Ang/Tie-2 system is involved in the growth and development of metastases of GEP-NETs, and that favors the recruitment of Tie-2(+) monocytes to the tumor site, where they can promote inflammation and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20696814     DOI: 10.1677/ERC-10-0020

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  10 in total

1.  Angiopoietin-2 levels are associated with retinopathy and predict mortality in Malawian children with cerebral malaria: a retrospective case-control study*.

Authors:  Andrea L Conroy; Simon J Glover; Michael Hawkes; Laura K Erdman; Karl B Seydel; Terrie E Taylor; Malcolm E Molyneux; Kevin C Kain
Journal:  Crit Care Med       Date:  2012-03       Impact factor: 7.598

2.  Angiogenic factors as prognostic markers in neuroendocrine neoplasms.

Authors:  Giulia Puliani; Franz Sesti; Emanuela Anastasi; Monica Verrico; Maria Grazia Tarsitano; Tiziana Feola; Federica Campolo; Cira Rosaria Tiziana Di Gioia; Mary Anna Venneri; Antonio Angeloni; Marialuisa Appetecchia; Andrea Lenzi; Andrea Marcello Isidori; Antongiulio Faggiano; Elisa Giannetta
Journal:  Endocrine       Date:  2022-01-28       Impact factor: 3.925

3.  Influence of Stress and Depression on the Immune System in Patients Evaluated in an Anti-aging Unit.

Authors:  Beatriz Cañas-González; Alonso Fernández-Nistal; Juan M Ramírez; Vicente Martínez-Fernández
Journal:  Front Psychol       Date:  2020-08-04

4.  Elevated peripheral blood plasma concentrations of tie-2 and angiopoietin 2 in patients with neuroendocrine tumors.

Authors:  Gabriela Melen-Mucha; Agata Niedziela; Slawomir Mucha; Ewelina Motylewska; Hanna Lawnicka; Jan Komorowski; Henryk Stepien
Journal:  Int J Mol Sci       Date:  2012-01-31       Impact factor: 6.208

5.  TIE-2 expressing monocytes in human cancers.

Authors:  Riccardo Turrini; Angélique Pabois; Ioannis Xenarios; George Coukos; Jean-François Delaloye; Marie-Agnès Doucey
Journal:  Oncoimmunology       Date:  2017-03-16       Impact factor: 8.110

6.  All-trans retinoic acid suppresses the angiopoietin-Tie2 pathway and inhibits angiogenesis and metastasis in esophageal squamous cell carcinoma.

Authors:  Na Li; Yanjuan Lu; Daoming Li; Xiangyu Zheng; Jingyao Lian; Shanshan Li; Huijuan Cui; Linda Zhang; Luqian Sang; Ying Wang; Jane J Yu; Taiying Lu
Journal:  PLoS One       Date:  2017-04-03       Impact factor: 3.240

Review 7.  An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Jiayun M Fang; Jay Li; Jiaqi Shi
Journal:  World J Gastroenterol       Date:  2022-03-14       Impact factor: 5.374

Review 8.  Circulating Angiogenic Markers in Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review.

Authors:  Irina Sandra; Irina Mihaela Cazacu; Vlad Mihai Croitoru; Mariana Mihaila; Vlad Herlea; Mircea Mihai Diculescu; Simona Olimpia Dima; Adina Emilia Croitoru
Journal:  Curr Issues Mol Biol       Date:  2022-09-04       Impact factor: 2.976

Review 9.  Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications.

Authors:  Eleonora Lauricella; Barbara Mandriani; Federica Cavallo; Gaetano Pezzicoli; Nada Chaoul; Camillo Porta; Mauro Cives
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

10.  Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.

Authors:  Miguel Sampedro-Núñez; Raúl M Luque; Ana M Ramos-Levi; Manuel D Gahete; Ana Serrano-Somavilla; Alicia Villa-Osaba; Magdalena Adrados; Alejandro Ibáñez-Costa; Elena Martín-Pérez; Michael D Culler; Mónica Marazuela; Justo P Castaño
Journal:  Oncotarget       Date:  2016-02-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.